Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai's Lorqess Setback Puts Focus Squarely on Eribulin

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai's recently acquired weight loss drug Lorqess appears set for failure in the hands of U.S. FDA, and while approval rejection would have a small direct impact on the company, the pending approval of eribulin becomes even more vital to a company trying to offset upcoming years of patent losses

You may also be interested in...

Selective Trial Populations Weigh Against Advisory Panel Support For Lorqess

Committee votes 9 to 5 vote against approval of Arena's weight loss drug, troubled that the study populations didn't reflect the real world.

Takeda Bulks Up In Obesity With Orexigen Deal

Takeda, already a strong player in diabetes, is looking to be a leader in obesity as well. Obesity is a risky area of drug development, given regulatory concerns about safety and efficacy, not to mention payer resistance. But despite those roadblocks, Takeda added to its substantial obesity pipeline through a deal with Orexigen Therapeutics, announced Sept. 2

Astellas, Eisai Tout Pipeline Updates In Face Of Patent Losses: Japanese Earnings Roundup (Part 1 Of 2)

TOKYO - Japanese pharma are responding to patent cliffs much like their Western counterparts, through lifecycle management, cost containment and increased focus on emerging markets. In Part 1 of PharmAsia News' roundup of the Japanese Q1 earnings season, Astellas and Eisai respond to patent loss of blockbuster products by highlighting product development milestones and patent extensions

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts